SoftMining

SoftMining is an Italian AI-powered drug discovery company that integrates artificial intelligence, laboratory robotics, and network biology to streamline the research and development of new therapeutics and biomaterials. The company utilizes its proprietary ADAPT platform to map complex biological networks, design and test molecules, and coordinate interdisciplinary data. By shifting away from traditional, linear drug discovery models toward a continuous AI-robotic loop, SoftMining aims to reach preclinical readiness in approximately six months. Their approach focuses on multi-layer interaction systems rather than single-target analysis, supported by expertise in chemoinformatics, medicinal chemistry, and materials science.

This technology is designed to help pharmaceutical companies and biotech labs de-risk their discovery pipelines, lower costs, and shorten timelines for bringing new drugs to market. The company has a history of developing candidates for neurodegenerative diseases, antibiotics, and oncology treatments, as well as innovative biomaterials like PVC replacements. Beyond its core drug discovery work, SoftMining leverages its computational expertise for applications in digital health and semantic analysis, having previously contributed to public health efforts with contact-tracing technology. The firm collaborates on international research projects and maintains a portfolio of patents covering its methodologies and experimental outcomes.